ct-868
Peptideexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 12, 2021 (NCT04973111)
Timeline
Indications
Mechanism of action
GIP agonist
GLP1R agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06062069 | Phase 2 | Oct 19, 2023 | Carmot Therapeutics, Inc., Roche |
| NCT05794581 | Phase 1 | Mar 21, 2023 | Carmot Therapeutics, Inc. |
| NCT05110846 | Phase 2 | Dec 8, 2021 | Carmot Therapeutics, Inc. |
| NCT04973111 | Phase 1 | Jul 12, 2021 | Carmot Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Carmot Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2021 |
| Roche | For profit | 1 | 0 | 1 | 2023 |
2 organizations
Page 1 / 1